Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241210106 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lea Helena Kunze und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. Hauptthemen laut MEDLINE: Tauopathies, Alzheimer Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Munich Cluster for Systems Neurology, Alzheimer's Association Grant, AD Strategic Fund, Deutsche Forschungsgemeinschaft (DFG).
Abstract (Originalsprache)
Neuroinflammation is one disease hallmark on the road to neurodegeneration in primary tauopathies. Thus, immunomodulation might be a suitable treatment strategy to delay or even prevent the occurrence of symptoms and thus relieve the burden for patients and caregivers. In recent years, the peroxisome proliferator-activated receptor γ (PPARγ) has received increasing attention as it is immediately involved in the regulation of the immune system and can be targeted by the anti-diabetic drug pioglitazone. Previous studies have shown significant immunomodulation in amyloid-β (Aβ) mouse models by pioglitazone. In this study, we performed long-term treatment over six months in P301S mice as a tauopathy model with either pioglitazone or placebo. We performed serial 18 kDa translocator protein positron-emission-tomography (TSPO-PET) imaging and terminal immunohistochemistry to assess microglial activation during treatment. Tau pathology was quantified via immunohistochemistry at the end of the study. Long-term pioglitazone treatment had no significant effect on TSPO-PET, immunohistochemistry read-outs of microglial activation, or tau pathology levels in P301S mice. Thus, we conclude that pioglitazone modifies the time course of Aβ-dependent microglial activation, but does not significantly modulate microglial activation in response to tau pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.
- German Center for Neurodegenerative Diseases (DZNE) Munich, Feodor-Lynen-Str. 17, 81377 Munich, Germany.
- Department of Radiology, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.
- Munich Cluster for Systems Neurology (SyNergy), Ludwig Maximilian University of Munich, 81377 Munich, Germany.
- Center for Neuropathology and Prion Research, LMU Munich, Feodor-Lynen-Str. 23, 81377 Munich, Germany.
ORCID-Profile: Lea Helena Kunze, Gloria Biechele, Lars Paeger, Sabina Tahirovic
Förderung
- Munich Cluster for Systems Neurology
- Alzheimer's Association Grant, AD Strategic Fund
- Deutsche Forschungsgemeinschaft (DFG)
- Alzheimer’s Association Grant, AD Strategic Fund
Zitieren
APA
Kunze, L. H., Ruch, F., Biechele, G., Eckenweber, F., Wind-Mark, K., Dinkel, L., Feyen, P., Bartenstein, P., Ziegler, S., Paeger, L., Tahirovic, S., Herms, J., & Brendel, M. (2023). Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210106
Vancouver
Kunze LH, Ruch F, Biechele G, Eckenweber F, Wind-Mark K, Dinkel L, et al. Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210106
BibTeX
@article{Kunze2023,
author = {Kunze, Lea Helena and Ruch, François and Biechele, Gloria and Eckenweber, Florian and Wind-Mark, Karin and Dinkel, Lina and Feyen, Paul and Bartenstein, Peter and Ziegler, Sibylle and Paeger, Lars and Tahirovic, Sabina and Herms, Jochen and Brendel, Matthias},
title = {Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241210106}
}
EUVIMED